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INTRODUCTION
Rupture of tendons due to either high load or laceration is
a common injury, especially for the hand. Tendon
disorders are traditionally treated by reducing inflamma-
tion, restoring flexibility, and, if necessary, performing
surgical repair.[1] It has been estimated that hand surgeons
repair nearly one-third of a million digital flexor tendon
injuries per year in the United States.[2] Despite the fact
that surgery of tendons is a common procedure, its
outcome is often unsatisfactory. Recovery after tendon
surgery can take months. At best, the restored tendon is
about half of its initial mechanical properties, so surgeons
often face patients’ dissatisfaction. On the other hand, if
left untreated, healing tendon is not as good as original
structure from a mechanical point of view. Moreover, the
related pain is difficult to treat.
Several factors may explain these unsatisfactory results
such as the difficulty to anchorage the tendon in muscle,
the high mechanical constraint on the repair structure, or
the unavailability of ideal tendon grafts (currently, tendon
grafts are either auto, allo, or synthetic). It has been shown
that early mobilization following tendon surgery gives
superior results.[3] The repaired tendon should then be
able to support immediate loading. However, suturing
techniques to joint split ends of tendons, while providing
sufficient mechanical strength to limit gapping, are
inadequate to carry normal loads.
Based on the shortcomings of the actual tendon
surgery, tendon tissue engineering may offer an alterna-
tive approach. The objective in developing an engineered
tendon will then be the reconstruction of the injured
structure with structural and functional properties as good
as the original. Moreover, an engineered tendon could
reduce the rate of secondary problems by making the
surgical procedure less extensive.
This article gives first some general details on anatomy
and physiological properties of tendons, followed by a list
of requirements for an ideal engineered tendon. A review
of the actual state of the art in tendon replacement is then
performed, and finally, some remarks on the future of
tissue engineering of tendons are proposed.
ANATOMICAL AND PHYSIOLOGICAL
PROPERTIES OF TENDONS
Tendons are dense, regularly organized, and by their
arranged collagen fibers, allow connection between
muscles and bones. The structure is composed of long
arranged collagen fibers, and the function and behavior of
tendons depend on of their mechanical properties.
They are capable of resisting important strength in
order to transmit the muscular power to the bones and
articulations. They protect the muscle (fascia) and fix the
length of the muscle belly. They also play a role of damper
and shock absorber.
A tendon is composed of multiple fascicles surrounded
by a fascicular membrane and septa. Inside the fascicle,
we find a mix of fibroblasts in relative central position and
fibrils. The fibrils are composed of microfibrils, which
themselves are made of tropocollagen.
The fascicular membrane is the endotenon, which is
draped over by a sliding structure, the peritendon.
Between the peritendon and the endotenon run vessels,
nerve, and lymphatics. Depending on the localization, the
organization of the surrounding layers is more complex.
A hand flexor tendon is encircled by a well-
defined sheath covered by synovial cells. In this
situation, the external layer (paratenon) is called
tenosynovium, but if there is no synovial lining, the
paratenon is called tenovagium.
At the musculo-tendinous junction, the perimysium is
continuous with the endotenon. At the other extremity on
the tendon–bone interface, the collagen fibers and the
endotenon become continuous with the periosteum.
The tendon insertion into bone is of two types. The first
one described by Cooper and Misol,[4] shows a transition
from the tendon to a layer of fibrocartilage with
digitations in the periosteum. The fibrocartilage is
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progressively ossified and merges with bone. The second
one is more complex and is characterized by having the
periorteum as an intermediate layer. Superficial fibrils are
fixed into the periosteum and deeper, directly into bone.
Tendon is largely vascularized, the blood flow
coming from the perymisium, periosteum attachment,
and surrounding tissues. In particular, the perfusion
through the surrounding tissue reaches the tendon
penetrating the paratenon, the mesotenon, or vincula.
We can separate vascularized from avascular tendons:
vascularized tendons concern those with a rich surround-
ing vascularization, which penetrate directly inside the
endotenon. The avascular tendons are contained in a
sheath, and the vessels are penetrating through thin
structure (mesotendon or vincula), which reticulate and
bind the tendon.
The innervation plays a sensory role through mecano-
receptors located near the musculo-tendinous junction.
REQUIREMENTS FOR TISSUE
ENGINEERING OF TENDON
Several requirements need to be fulfilled in the tissue
engineering of tendons. Some are common to most
engineered tissues used for applications in musculo-




1. It is usually stated that an engineered tissue is
composed of three elements: scaffold, cells, and
growth factors. Tissue engineering is then, by
definition, multi-disciplinary. In order to bring useful
and adequate solutions, it is especially important that
physicians, who will be the users of the developed
engineered tissue, are involved at every step of the
project development. For example, surgical proce-
dures should be anticipated since the beginning of the
project to insure that the developed tissue will be
manageable in the constraint environment of a
surgical room.
2. As a basic rule, the engineered tissue should be easy
to use and its manipulation should be as close as
possible to the actual standard surgical procedures.
3. The engineered tissue will need to be approved by
governmental agencies (e.g., FDA) before being
available on the market. Especially if cells and/or
growth factors are used, it is important to be aware of
the tests required by these governmental agencies to
obtain an approval for clinical use. This would avoid
the repetition of experiments not following estab-
lished standards.
Specific Requirements for Tendon
Tissue Engineering
1. Tendon auto-grafts are freely available during sur-
gery. Due to economical constraints on the health care
system, it would be difficult to propose an expensive
engineered tendon. The only economical factors,
which may favor the use of an engineered tendon
from the health insurance point of view, would be the
reduction of the operative time and a faster patient
recovery. Based on these economical considerations,
the production and stock management of the engi-
neered tendons should be considered from the
beginning of the project.
2. Tendon biomechanics is complex due to its non-
linear stress–strain relationship and viscoelasticity
(Fig. 1).[5,6] In-vivo forces quantification of tendons
is also a useful approach for the determination of
Fig. 1 Experimental and theoretical stress–strain curves
obtained at four different rates of elongation for one human
patellar tendon specimen. Good correlation between experimen-
tal and theoretical curves are found. The proposed constitutive
law with only three parameters is then able to fit nonlinear stress–
strain curves obtained at different strain rates. (Reproduced with
permission from Ref. [6].)
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mechanical design parameters.[7] An engineered
tendon should be able to reproduce these mechan-
ical behaviors. It should be noted that different ten-
dons might present different mechanical properties
as has been shown for fatigue damage.[8]
3. Fixation on bone and muscle may be the weakness
mechanical part of the engineered tendon. It is then
important to incorporate this point in the design of the
tendon. For example, it has to be decided early in the
project if the scaffold will be sutured or glued to the
muscle. In case of high mechanical constraints (early
loading), it would be more advisable to suture than to
glue the tendon. However, the drawback of tendon
suturing is the possibility of inducing a devascular-
ization of the tendon and a corresponding necrosis of
the tissue. It should be noted that if left untreated,
some tendons might spontaneously heal, suggesting
that the gluing process of tendon to muscle is a normal
way of healing.
4. Tendon cells must communicate to sustain growth and
matrix expression.[9] It has been shown that cells in the
epitenon and internal compartment of whole tendon
are connected physically to each other and express gap
junctions.[10] Successful engineered tendon replace-
ments must include designs that allow for cell-to-cell
connectivity to allow intercellular communication.
Scaffolds should then be easily seeded by cells and
encourage cell division and matrix expression.[9]
5. If tendon fibroblasts are used, it has to be noted that
these cells are site-dependent and may induce
different results regarding proliferation and/or gene
expression.[11,12] Autologous cells’ transplantation
has the advantage of not inducing immune reaction
and is more easily implemented from a regulatory
point of view. However, an initial biopsy followed by
a cellular expansion period is necessary, rendering
this approach time consuming. Disadvantages of
autologous cells’ transplantation disappear with
allogous cells’ transplantation, but the benefit of no
immune reaction and easier regulatory implementa-
tion are, on the other hand, lost. A careful selection of
the cells used, depending on the application, should
then be performed.
ACTUAL APPROACHES FOR TISSUE
ENGINEERING OF TENDON
In the term tissue engineering, we consider all the
engineering and biological approaches used in the devel-
opment of an artificial tendon. Different solutions proposed
for treating tendon rupture are presented from the scaffold,
cells, and growth factor/gene therapy points of view.
Scaffold
In order to bridge tendon lesions, synthetic scaffolds have
been used with relatively modest success.[13] Synthetic
tendon made of DacronTM, nylon, or even carbon fibers
has been used. One of the only synthetic scaffolds
remaining on the market is the Leeds-Keio ligament
made of polyethylene terephthalate (PET). Recently, it has
been shown that treatment with radiofrequency (RF)-
generated glow discharge increased cell attachment and
proliferation on this PET implant.[14]
Organic polymers’ matrix, such as acellular collagen,
have also been employed as tendon graft.[15] These
scaffolds are supposed to provide early mechanical sup-
port and promote cellular infiltration. However, achilles
tendon repairs using collagen scaffold achieved only
36% of normal maximum force.[16] Naturally occurring
extracellular matrices were also proposed for tendon
repair. There are limited locations within the body that
can be used as the source of these extracellular matrices.
One is derived from porcine small intestinal submuco-
sa.[17] With this tissue used as tendon scaffold, a
transient and significant weakening of mechanical
properties was found compared to patellar tendon in
the first months after implantation in an animal study.
After 12 months, no difference was found. In order to
increase the mechanical properties of the scaffold, col-
lagen scaffold with poly-L-lactic acid was developed.[18]
Mechanical properties were increased with this method.
Probably one of the most promising scaffold develop-
ments from biomechanical and biocompatible points
of view would be based on biomimetic strategy. In this
approach, the scaffold should include polymeric col-
lagen as the fundamental fibrous phase and being cross-
linked to give the mechanical strength of the engineered
tendon. To this end, derived from skate egg capsule, a
collagen-based scaffold was developed.[11] Fibers pro-
duced from pepsin-solubilized, bovine tendon type I
collagen were polymerized with di-catechol nordihydro-
guaiaretic acid (NDGA). These NDGA cross-linked
fibers showed high mechanical properties comparable
to native tendon and demonstrated excellent biocompat-
ibility properties.[19]
Cells
As for other engineered tissues (e.g., bone, cartilage),
incorporation of cells is supposed to increase the healing
potential of the tissues. A combination of scaffold and
cells is then developed, the scaffold playing either the role
of cell delivery system alone or cell delivery system and
mechanical support.
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Use of autologous mesenchymal stem cells seeded in
collagen gel in vitro and then implanted in the body has
been proposed.[20] The results indicated that delivering
mesenchymal stem cell–contracted, organized collagen
implants to large tendon defects could significantly
improve the biomechanics, structure, and probably the
function of the tendon after injury.[21] Mesenchymal stem
cells, which have the potential to differentiate in (tendon)
fibroblasts, hold the promise to be used for allogous cells’
transplantation. However, if the cells are not oriented in
the gel, only modest improved biomechanical properties
are observed compared to natural repair of unfilled
defect.[22] The orientation of the cells in the gel, in
particular due to the gel contraction mediated by cells,
improved the biomechanical propreties.[23] Besides mes-
enchymal stem cells, it may be useful to use differenti-
ated fibroblasts in order to speed up the healing process.
Moreover, fibroblasts seeded on a scaffold and in vitro
mechanically stimulated the mechanical properties of the
graft.[24] So, it has then been proposed that the delay
between rupture and surgery may be used to engineer the
tendon in vitro by applying mechanical stimulus. This
approach may, however, be difficult to apply from an
economical point of view. In order to amplify the
potential of cells in the healing process, autologous
mesenchymal stem cells might be genetically modified to
produce growth factors useful in the healing process
of tendon.[25]
Growth Factor/Gene Therapy
Use of growth factors is related to a good understanding of
the tendon healing process. This healing process could be
viewed as four overlapping phases: hemorrhagic, inflam-
matory, proliferation, and remodeling/maturation. The
second phase, inflammatory, is probably a key phase as
many different growth factors and cytokines are produced
and will drive the outcome process of healing. A detailed
description of these phases may be found in Ref. [26]. It
has been shown that treatment with growth factors such as
PDGF and IGF-1 stimulate DNA synthesis of tendon
fibroblasts.[27] However, as for other tissues, issues such
as the difficulty to deliver the growth factors or the
supraphysiologic concentrations needed to induce an
effect[28] need to be solved. A potential solution might be
the use of gene therapy. Genetically modified cells[25,27]
or gene-activated matrix[29] might be used to target spe-
cific location (ruptured zone of the tendon) and specific
biological process (healing of the tendon). This approach
is still in its infancy, but promising results have already
been obtained.
FUTURE DEVELOPMENT FOR TISSUE
ENGINEERING OF TENDONS
As mentioned by Hildebrand,[25] the regeneration of
normal tendon has not been achieved and further refine-
ments are necessary for these treatments. Indeed, none of
the actual solutions followed all the requirements noted
earlier for tissue engineering of tendons. Especially,
problems like fixations of tendons, incorporation of
biomechanical properties, choice of scaffold with ade-
quate degradation properties, or packaging of the engi-
neered tendon[20] still need to be solved. Nature used
millions of evolution years to optimize the functionality of
the tendons. It might then be worthy to use this knowl-
edge in order to engineer tendons. The combination of
biomimetism, as proposed by Koob[11] to engineer ten-
don scaffold, and gene therapy, either with cells, e.g.,
Ref. [25], or with gene activated matrix[29] to target
specific healing tendon process, held probably the most
promising development in tissue engineering of tendon.
CONCLUSION
Important progresses have been achieved recently in
tissue engineering. Although no ideal solution exists for
tissue engineering of tendons, it is reasonable to believe
that good solutions will emerge from laboratories. In
particular, the combination of biomimetism and gene
therapy with mesenchymal stem cells opens new fields of
possibilities from a scientific and clinical point of view.
However, the development of tissue engineering of
tendons can only be successful if the challenging econo-
mical constraints are satisfied. Based on the past industrial
experiences in tissue engineering for bone or cartilage, it
would be an illusion to believe that engineered tendon
with cells may be entirely supported by private industries.
It seems more reasonable to develop collaborations
between industries and hospitals. The industries would
be responsible for developing and managing the scaffolds,
and the hospitals would be responsible for managing the
cells’ bank and seeding process of the scaffolds with the
selected cells. With this kind of strategy, it is hoped that,
in the future, surgeons will no more face the paradox of
treating a ruptured tendon by collecting another tendon in
the patient.
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